Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Under Armour Inc Class A — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Under Armour Inc Class A trades at $4.67 (market cap $2.08B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.3× Under Armour Inc Class A's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Under Armour Inc Class A for 19 Days on average.
| TVTX | UA | |
|---|---|---|
Market Cap | $4.88B | $2.08B |
Volume | 1,668,577 | 2,142,599 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $7.88 |
52-Week Low | $26.79 | $3.96 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $5.01B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Under Armour (UA) trades at $4.76, down 0.63% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly earnings with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst sentiment is divided with 40% buy ratings, though recent news highlights revenue guidance cuts and competitive pressures.
The outlook remains challenging with persistent revenue declines and negative margins offset by attractive valuation multiples. Investment opportunity lies in potential turnaround execution, while risks include sustained consumer demand weakness and execution missteps in a highly competitive athletic apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
